公开(公告)号：US20240075125A1

公开(公告)日：2024-03-07

申请号：US18200421

申请日：2023-05-22

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Alessandra Vitelli ,  Alfredo Nicosia ,  Riccardo Cortese

IPC: A61K39/145 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  C12N15/85 ,  C12N15/86

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  C12N15/85 ,  C12N15/86 ,  A61K2039/53

Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.

公开(公告)号：US20170044571A1

公开(公告)日：2017-02-16

申请号：US15339225

申请日：2016-10-31

Applicant: The Government of the United States of America as Represented by the Secretary of the Department of ,  GlaxoSmithKline Biologicals SA

Inventor： Nancy J. Sullivan ,  Gary J Nabel ,  Clement Asiedu ,  Cheng Cheng ,  Alfredo Nicosia ,  Riccardo Cortese ,  Virginia Ammendola ,  Stefano Colloca

IPC: C12N15/86 ,  C12N7/00 ,  C07K14/005

Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Abstract translation: 本发明提供用于诱导免疫应答的疫苗和针对用于人类预防性疫苗的禽流感病毒感染的保护。 特别地，本发明提供了表达来自不同的埃博病毒（EBOV）或马尔堡病毒（MARV）病毒的病毒蛋白的黑猩猩腺病毒载体。

公开(公告)号：US10584355B2

公开(公告)日：2020-03-10

申请号：US15339225

申请日：2016-10-31

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nancy J. Sullivan ,  Gary J Nabel ,  Clement Asiedu ,  Cheng Cheng ,  Alfredo Nicosia ,  Riccardo Cortese ,  Virginia Ammendola ,  Stefano Colloca

IPC: C12N15/86 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

公开(公告)号：US11498956B2

公开(公告)日：2022-11-15

申请号：US16327575

申请日：2017-08-23

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  UNIVERSITY OF COPENHAGEN

Inventor： Maria Rosaria Bassi ,  Riccardo Cortese ,  Anna Morena D'Alise ,  Antonella Folgori ,  Peter Johannes Holst ,  Alfredo Nicosia

IPC: C07K14/74 ,  A61P31/20 ,  A61P35/00 ,  A61K39/00 ,  A61K39/29 ,  C07K14/005

Abstract: The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.

公开(公告)号：US11254711B2

公开(公告)日：2022-02-22

申请号：US15735872

申请日：2016-06-10

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Virginia Ammendola ,  Stefano Colloca ,  Riccardo Cortese ,  Fabiana Grazioli ,  Alfredo Nicosia ,  Alessandra Vitelli

IPC: C07K14/005 ,  C12N15/86 ,  C07K14/075 ,  A61K39/12 ,  A61K39/21 ,  C07K14/75 ,  C12N15/861 ,  A61K39/155 ,  C12N7/00 ,  A61K39/00

Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1,
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

公开(公告)号：US11254710B2

公开(公告)日：2022-02-22

申请号：US15735839

申请日：2016-06-10

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Stefano Colloca ,  Virginia Ammendola ,  Fabiana Grazioli ,  Alessandra Franz Vitelli ,  Alfredo Nicosia ,  Riccardo Cortese

IPC: C07H21/04 ,  C07K14/005 ,  C12N15/86 ,  C07K14/075 ,  C07K14/75 ,  A61K39/12 ,  C12N15/861 ,  A61K39/155 ,  A61K39/21 ,  C12N7/00 ,  A61K39/00

Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

公开(公告)号：US11214599B2

公开(公告)日：2022-01-04

申请号：US16710131

申请日：2019-12-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano Colloca ,  Alfredo Nicosia ,  Riccardo Cortese ,  Virginia Ammendola ,  Maria Ambrosio

IPC: C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N15/861 ,  A61K39/12 ,  A61K39/235 ,  A61K48/00 ,  A61K39/00

Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

公开(公告)号：US20240091338A1

公开(公告)日：2024-03-21

申请号：US18115556

申请日：2023-02-28

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Alfredo Nicosia ,  Ricardo Cortese ,  Alessandra Vitelli

IPC: A61K39/155 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275 ,  A61K2039/545

Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.

公开(公告)号：US11278614B2

公开(公告)日：2022-03-22

申请号：US16782268

申请日：2020-02-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano Colloca ,  Riccardo Cortese ,  Antonella Folgori ,  Alfredo Nicosia

IPC: C12N15/863 ,  A61K39/00 ,  C07K14/74 ,  C07K14/005 ,  A61K39/29 ,  C12N7/00 ,  C12N15/86

Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.

公开(公告)号：US11701422B2

公开(公告)日：2023-07-18

申请号：US16800384

申请日：2020-02-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Alessandra Vitelli ,  Alfredo Nicosia ,  Riccardo Cortese

IPC: A61K39/155 ,  A61K39/145 ,  A61K39/12 ,  C07K14/005 ,  C12N15/85 ,  C12N15/86 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  C12N15/85 ,  C12N15/86 ,  A61K2039/53 ,  C12N2710/10343 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2800/22 ,  C12N2840/20

Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.